OraSure Technologies

OSUR · NASDAQ

$3.75+$0.065 (+1.77%)TodayMarket closed ·
Prev close $3.68

About OSUR

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 500 full-time employees. The Company, together with its wholly owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is engaged in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Its products and services include OraQuick ADVANCE Rapid HIV 1/2 Antibody Test, OraQuick HIV Self-Test, Diagnostics Direct Syphilis Health Check, OraQuick Ebola Rapid Antigen Test, InteliSwab COVID-19 Rapid Test Pro, and SickleSCAN Test, among others. Its portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct consumers.

Employees
500
Headquarters
Bethlehem, Pennsylvania
Listed
Nov 17, 1986
Sector
Health Care
Industry
Health Care Equipment & Supplies

Leadership

OraSure Technologies executives
NameTitleSince
John Kenny——
Carrie Eglinton Manner—2022
Kenneth Mcgrath——
Anne Messing——
Steven Boyd——
Nancy Gagliano—2021
Lelio Marmora——
Robert Mcmahon——
Jason Plagman—2023

Revenue by product and region

Fiscal year ended Dec 31, 2025: $115.02M total revenue

By product

  • Products and services$109.06M94.8%
  • Other$5.97M5.2%

By region

  • United States$78.25M68.0%
  • Africa$23.99M20.9%
  • Europe$7.39M6.4%
  • Other regions$5.38M4.7%

Similar companies

Companies in the same industry as OraSure Technologies

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.